ABT-773 Abbott Laboratories

Current Opinion in Investigational Drugs

Volumn 2, Issue 6, 2001, Pages 766-772

  Lawrence, L E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CETHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; HMR 3004; KETOLIDE; MACROLIDE; PENICILLIN G; PLACEBO; TELITHROMYCIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; CHEMICAL MODIFICATION; CLINICAL TRIAL; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DESIGN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERANCE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS; ERYTHROMYCIN; HUMANS; KETOLIDES; RESPIRATORY TRACT INFECTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034795152     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Abbott and Taisho to collaborate on development of next-generation antibiotics
2. Merrill Lynch: Abbott Laboratories
3. Efficacy of ABT-773 against acute systemic bacterial infections in mice caused by resistant Streptococcus pneumoniae
4. Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics
5. 1999 Annual shareholders meeting: Review of Abbott's business operations
6. The in vitro activity of the ketolides ABT-773 and HMR-3004 as measured by broth microdilution against macrolide susceptible and macrolide resistant Streptococcus sp
7. In brief: Alteon Pimagedine
8. Design, synthesis and characterization of ABT-773: A novel ketolide highly active against multidrug-resistant pathogens
9. Molecular basis of ABT-773 activity against erm-containing macrolide-resistant S pneumoniae
10. Mechanism of action of novel ketolide ABT-773
11. Preclinical pharmacokinetic profile of ABT-773 in mouse, rat, monkey and dog
12. 14C]ABT-773
13. Efficacies of ABT-773 and HMR-3647 against respiratory pathogens causing acute systemic infections in mice and lung infections in rats
14. Efficacies of ABT-773 and azithromycin against experimental rat lung infections caused by Streptococcus pneumoniae
15. Taisho's ketolide antibiotic to enter PII in Japan next June
16. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Morexella catarrhalis
17. Aventis Ketek NDA includes four indications, in vitro resistant pathogen data
18. Design, synthesis and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens
19. Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides
20. In vitro activity of ABT-773, a new ketolide antibiotic, against Chlamydia pneumoniae
21. Antipneumococcal activity of ABT-773 compared to those of 10 other agents
22. Efficacy of ABT-773 (ABT), a new ketolide, versus erythromycin (ERY) against penicillin (Peni)/Ery sensitive and macrolide resistant Streptococcus pneumoniae (sp) in a mouse pneumonia model
23. Bacterial kill of ABT-773 in a murine pneumococcal pneumoniae model
24. Oral telithromycin (HMR 3647; 800 mg OD) for 5 days and 10 days is well tolerated and as effective as amoxicillin/clavulanic acid (500/125 mg TID) for 10 days in acute maxillary sinusitis (AMS) in adults
25. In vitro activities of ABT-773, telithromycin and 8 other antimicrobials against erythromycin-resistant Streptococcus pneumoniae isolates from the respiratory tracts of children
26. The in vitro activities of ABT-773, telithromycin and other macrolides against Canadian streptococci
27. The in vitro activity of ABT-773, a new ketolide, against major respiratory pathogens
28. Single oral dose pharmacokinetics and safety of ABT-773 in healthy subjects
29. The bioavailability of ABT-773 is unaffected by food
30. In vivo pharmacodynamics of ABT-773, a new ketolide antibiotic
31. Impact of macrolide resistance on the in vivo activity of ABT-773 on Streptococcus pneumoniae
32. In vitro activity of ABT-773 against invasive strains of Streptococcus pneumoniae
33. Studies of the novel ketolide ABT-773: Transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae
34. In vitro activities of a new ketolide, ABT-773, alone and in combination with amoxicillin, metronidazole, or tetracycline against Helicobacter pylori
35. Taisho: Overseas R&D spending cuts into net profits
36. Drug development pipeline
37. Structure-activity relationship for six ketolide antibiotics
38. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria
39. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents
40. Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model
41. In vitro activity of ABT-773 against anaerobic bacteria
42. ABT-773